Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116844 · ClinicalTrials.gov registry record · Phase 4
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 73
- Enrollment target
NCT00116844 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 73 participants.
The verdict
NCT00116844, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 73 participants
- Enrollment target
Study Summary
Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
Interventions
- DRUG Placebo
- DRUG Valaciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2005-03-29 |
| Est. Completion | 2006-01-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116844
The ClinicalTrials.gov registry entry for NCT00116844 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00116844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116844 about?
NCT00116844 is a clinical study titled "VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.". Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
What is the current status of trial NCT00116844?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 73 participants. The study started on 2005-03-29. Estimated completion is 2006-01-10.
What interventions are being tested in trial NCT00116844?
The interventions under investigation include: Placebo (DRUG), Valaciclovir (DRUG).
Who is sponsoring clinical trial NCT00116844?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.